{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:21:15Z","timestamp":1792027275464,"version":"4.4.0"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejinme.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.ejim.2016.10.007","type":"journal-article","created":{"date-parts":[[2016,10,23]],"date-time":"2016-10-23T07:15:17Z","timestamp":1477206917000},"page":"19-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":231,"special_numbering":"C","title":["The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal"],"prefix":"10.1016","volume":"37","author":[{"given":"Vincenzo","family":"Savarino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Dulbecco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"de Bortoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ottonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Savarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2016.10.007_bb0005","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1053\/j.gastro.2008.05.021","article-title":"Control of gastric acid in health and disease","volume":"134","author":"Shubert","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2016.10.007_bb0010","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1365-2036.2011.04742.x","article-title":"Oesophagealmotility and bolus transit abnormalities increase in parallel with the severity of gastro-oesophageal reflux disease","volume":"34","author":"Savarino","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejim.2016.10.007_bb0015","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1111\/nmo.12606","article-title":"Esophagogastric junction morphology is associated with a positive impedance\u2013pH monitoring in patients with GERD","volume":"27","author":"Tolone","year":"2015","journal-title":"Neurogastroenterol. Motil."},{"key":"10.1016\/j.ejim.2016.10.007_bb0020","first-page":"548","article-title":"Dysmotility and reflux disease","volume":"21","author":"Savarino","year":"2013","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.ejim.2016.10.007_bb0025","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/j.1875-9114.1997.tb03675.x","article-title":"Proton pump inhibitors and acid-related diseases","volume":"17","author":"Sachs","year":"1997","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejim.2016.10.007_bb0030","first-page":"109","article-title":"Pharmacological control of gastric acid secretion for the treatment of acid-related peptic disease: past, present, and future","volume":"98","author":"Aihara","year":"2003","journal-title":"Pharmacol. Res."},{"issue":"10","key":"10.1016\/j.ejim.2016.10.007_bb0035","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1517\/17425255.2013.813018","article-title":"The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment","volume":"9","author":"de Bortoli","year":"2013","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejim.2016.10.007_bb0040","first-page":"1","article-title":"Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations","volume":"8","author":"Savarino","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"9","key":"10.1016\/j.ejim.2016.10.007_bb0045","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1136\/gut.28.9.1120","article-title":"Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs","volume":"28","author":"Jones","year":"1987","journal-title":"Gut"},{"issue":"Suppl. 1","key":"10.1016\/j.ejim.2016.10.007_bb0050","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2036.1995.tb00778.x","article-title":"The role and limitations of H2 receptor antagonists in the treatment of gastro-esophageal reflux disease","volume":"9","author":"Colin-Jones","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl. 193","key":"10.1016\/j.ejim.2016.10.007_bb0055","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3109\/00365529209096000","article-title":"Tolerance during dosing with H2 receptor antagonists. An overview","volume":"27","author":"Wilder-Smith","year":"1992","journal-title":"Scand J Gastroenterol"},{"issue":"7","key":"10.1016\/j.ejim.2016.10.007_bb0060","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S1590-8658(01)80115-8","article-title":"Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor","volume":"33","author":"Tonini","year":"2001","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.ejim.2016.10.007_bb0065","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/pds.1969","article-title":"Marked increase in proton pump inhibitors use in Australia","volume":"19","author":"Hollingworth","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ejim.2016.10.007_bb0070","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/ajg.2016.166","article-title":"We are using too many PPIs, and we need to stop: a European perspective","volume":"111","author":"Lanas","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejim.2016.10.007_bb0075","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/bmj.39406.449456.BE","article-title":"Overprescribing proton pump inhibitors","volume":"336","author":"Forgacs","year":"2008","journal-title":"Br Med J"},{"key":"10.1016\/j.ejim.2016.10.007_bb0080","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/MAJ.0b013e31829f87d5","article-title":"Potential costs of inappropriate use of proton pump inhibiotrs","volume":"347","author":"Ladd","year":"2014","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.ejim.2016.10.007_bb0085","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1136\/pgmj.2006.051151","article-title":"Inappropriate prescribing of proton pump inhibitors in primary care","volume":"83","author":"Batuwitage","year":"2007","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.ejim.2016.10.007_bb0090","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.phrs.2008.09.016","article-title":"Proton pump inhibitors in GORD. An overview of their pharmacology, efficacy and safety","volume":"59","author":"Savarino","year":"2009","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ejim.2016.10.007_bb0095","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.dld.2007.09.008","article-title":"The lessons learned from randomized clinical trials of GERD","volume":"39","author":"Pace","year":"2007","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.ejim.2016.10.007_bb0100","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1136\/gut.2007.145177","article-title":"Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano\u2013Monghidoro study","volume":"57","author":"Zagari","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.ejim.2016.10.007_bb0105","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1572-0241.2007.01659.x","article-title":"Management strategy for patientswith gastroesophageal reflux disease: a comparison between empirical treatment with esomeprazole and endoscopy-oriented treatment","volume":"103","author":"Giannini","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ejim.2016.10.007_bb0110","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.dld.2004.03.019","article-title":"Combined multichannel intraluminal impedance and pH-metry: a novel technique to improve detection of gastro-oesophageal reflux. Literature review","volume":"36","author":"Zentilin","year":"2004","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.ejim.2016.10.007_bb0115","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nrgastro.2013.50","article-title":"NERD: an umbrella term including heterogeneous subpopulations","volume":"10","author":"Savarino","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2016.10.007_bb0120","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1111\/j.1572-0241.2008.02119.x","article-title":"The role of non-acid reflux in NERD \u2014 lessons learned from impedance\u2013pH monitoring in 150 patients off therapy","volume":"103","author":"Savarino","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ejim.2016.10.007_bb0125","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/nmo.12299","article-title":"Esophageal baseline impedance levels in patients with pathophysiological characteristics of functional heartburn","volume":"26","author":"Martinucci","year":"2014","journal-title":"Neurogastroenterol. Motil."},{"issue":"6","key":"10.1016\/j.ejim.2016.10.007_bb0130","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.cgh.2014.11.035","article-title":"Association between baseline impedance values and response proton pump inhibitors in patients with heartburn","volume":"13","author":"de Bortoli","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejim.2016.10.007_bb0135","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00535-011-0480-0","article-title":"Impedance\u2013pH reflux patterns can differentiate non-erosive reflux disease from functional heartburn patients","volume":"47","author":"Savarino","year":"2012","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.ejim.2016.10.007_bb0140","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s00464-014-3431-z","article-title":"European Association of Endoscopic Surgery (EAES). EAES recommendations for the management of gastroesophageal reflux disease","volume":"28","author":"Fuchs","year":"2014","journal-title":"Surg. Endosc."},{"key":"10.1016\/j.ejim.2016.10.007_bb0145","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/ajg.2016.156","article-title":"Long-term PPI use: balancing potential harms and documented benefits","volume":"111","author":"Laine","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejim.2016.10.007_bb0150","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1572-0241.2006.00998.x","article-title":"On-demand therapy for gastroesophageal reflux disease","volume":"102","author":"Metz","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ejim.2016.10.007_bb0155","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0016-5107(96)70055-X","article-title":"Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole","volume":"44","author":"Malesci","year":"1996","journal-title":"Gastrointest. Endosc."},{"key":"10.1016\/j.ejim.2016.10.007_bb0160","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.gtc.2015.02.010","article-title":"The effect of proton pump inhibitors on Barrett's esophagus","volume":"44","author":"Dunbar","year":"2015","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.ejim.2016.10.007_bb0165","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1111\/j.1572-0241.2004.30228.x","article-title":"Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus","volume":"99","author":"El-Serag","year":"2004","journal-title":"Am. J. Gastroenterol."},{"issue":"180","key":"10.1016\/j.ejim.2016.10.007_bb0170","doi-asserted-by":"crossref","first-page":"387","DOI":"10.5694\/j.1326-5377.2004.tb05991.x","article-title":"Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus","volume":"19","author":"Hillman","year":"2004","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.ejim.2016.10.007_bb0175","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.cgh.2012.11.014","article-title":"Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus","volume":"11","author":"Kastelein","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejim.2016.10.007_bb0180","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1749-6632.2011.06048.x","article-title":"Barrett's esophagus: proton pump inhibitors and chemoprevention II","volume":"1232","author":"Richter","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejim.2016.10.007_bb0185","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/BF01296437","article-title":"Helicobacter pylori and duodenal evidence suggesting causation","volume":"37","author":"Megraud","year":"1992","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejim.2016.10.007_bb0190","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-116-9-705","article-title":"Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric and duodenal ulcer \u2013 a randomized, controlled study","volume":"116","author":"Graham","year":"1992","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejim.2016.10.007_bb0195","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.dld.2015.06.010","article-title":"Guidelines for the management of Helicobacter pylori infection in Italy: the III Working Group Consensus Report 2015","volume":"47","author":"Zagari","year":"2015","journal-title":"Dig. Liver Dis."},{"issue":"6","key":"10.1016\/j.ejim.2016.10.007_bb0200","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009034.pub2","article-title":"Sequential versus standard triple first-line therapy for Helicobacter pylori eradication","volume":"28","author":"Nyssen","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"10.1016\/j.ejim.2016.10.007_bb0205","article-title":"Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients","volume":"18","author":"Ford","year":"2004","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejim.2016.10.007_bb0210","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.gastro.2016.04.006","article-title":"The Toronto consensus for the treatment of Helicobacter pylori infection in adults","volume":"151","author":"Fallone","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2016.10.007_bb0215","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1365-2036.2009.04105.x","article-title":"Review article: Helicobacter pylori-negative duodenal ulcer disease","volume":"30","author":"Gisbert","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl. 2","key":"10.1016\/j.ejim.2016.10.007_bb0220","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1046\/j.1365-2036.2001.00114.x","article-title":"Review article: role of proton pump inhibitors in non-H. pylori-related ulcers","volume":"15","author":"Freston","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejim.2016.10.007_bb0225","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1046\/j.1365-2036.1997.146322000.x","article-title":"Recurrence of duodenal ulcer after Helicobacter pylori eradication is related to high acid output","volume":"11","author":"Harris","year":"1997","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejim.2016.10.007_bb0230","first-page":"1409","article-title":"Helicobacter pylori-negative duodenal ulcers: prevalence, clinical characteristics, and prognosis\u2014results from a randomized trial with 2-year follow-up","volume":"96","author":"Bytzer","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejim.2016.10.007_bb0235","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1053\/bega.2001.0187","article-title":"Current indications for acid suppressants in Helicobacter pylori-negative ulcer disease","volume":"15","author":"Howden","year":"2001","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.ejim.2016.10.007_bb0240","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1136\/gutjnl-2012-302084","article-title":"Management of Helicobacter pylori infection\u2014the Maastricht IV\/Florence consensus report","volume":"61","author":"Malfertheiner","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.ejim.2016.10.007_bb0245","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1023\/A:1018834301901","article-title":"Effect of one-month treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) on gastric pH of rheumatoid arthritis patients","volume":"43","author":"Savarino","year":"1998","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejim.2016.10.007_bb0250","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2165\/00003495-199856030-00002","article-title":"Proton pump inhibitors \u2014 pharmacology and rationale for use in gastrointestinal disorders","volume":"56","author":"Richardson","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/j.ejim.2016.10.007_bb0255","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-230X-2-17","article-title":"Are proton pump inhibiotrs the first choice for acute treatment of gastric ulcers? A meta-analysis of randomized clinical trials","volume":"2","author":"Salas","year":"2002","journal-title":"BMC Gastroenterol"},{"issue":"Suppl. 4","key":"10.1016\/j.ejim.2016.10.007_bb0260","first-page":"S30","article-title":"The role of proton pump inhibitors in NSAID-associated gastropathy and upper gastrointestinal symptoms","volume":"3","author":"Laine","year":"2003","journal-title":"Rev Gastroenterol Disord"},{"key":"10.1016\/j.ejim.2016.10.007_bb0265","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002296","article-title":"Prevention of NSAID-induced gastroduodenal ulcers","author":"Rostom","year":"2002","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejim.2016.10.007_bb0270","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJM200103293441304","article-title":"Preventing recurrent upper gastrointestinal bleeding in patients with helicobacter pylori infection who are taking low-dose aspirin or naproxen","volume":"344","author":"Chan","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejim.2016.10.007_bb0275","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/ijcp.12634","article-title":"Should patients prescribed long-term low-dose aspirin receive proton pump inhibitors? A systematic review and meta-analysis","volume":"69","author":"Tran-Duy","year":"2015","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.ejim.2016.10.007_bb0280","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev.med.46.1.395","article-title":"Management of patients with Zollinger\u2013Ellison syndrome","volume":"46","author":"Meko","year":"1995","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.ejim.2016.10.007_bb0285","first-page":"468","article-title":"Control of gastric acid hypersecretion in themanagement of patients with Zollinger\u2013Ellison syndrome","volume":"17","author":"Metz","year":"1993","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejim.2016.10.007_bb0290","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.cgh.2011.08.012","article-title":"The Zollinger\u2013Ellison syndrome: dangers and consequences of interrupting antisecretory treatment","volume":"10","author":"Poitras","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2016.10.007_bb0295","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4137\/CGast.S9588","article-title":"Proton pump inhibitors use in hospitalized patients: is overutilization becoming a problem?","volume":"5","author":"Durand","year":"2012","journal-title":"Clin Med Insights Gastroenterol"},{"key":"10.1016\/j.ejim.2016.10.007_bb0300","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1038\/ajg.2009.49","article-title":"Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk in PPI","volume":"104","author":"Heidelbaugh","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejim.2016.10.007_bb0305","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1111\/j.1572-0241.2006.00839.x","article-title":"Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-intensive care unit hospitalized patients","volume":"101","author":"Heidelbaugh","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejim.2016.10.007_bb0310","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1053\/j.gastro.2016.02.011","article-title":"Gastroduodenal disorders","volume":"150","author":"Stanghellini","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2016.10.007_bb0315","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/gut.39.4.508","article-title":"Circadian gastric acidity in Helicobacter pylori positive ulcer patients with and without gastric metaplasia in the duodenum","volume":"39","author":"Savarino","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.ejim.2016.10.007_bb0320","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001960.pub3","article-title":"Pharmacological interventions for non-ulcer dyspepsia","author":"Moayyedi","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejim.2016.10.007_bb0325","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.cgh.2006.09.012","article-title":"Effects of proton pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials","volume":"5","author":"Wang","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejim.2016.10.007_bb0330","series-title":"Management of dyspepsia in adults in primary care","author":"National Institute for Clinical Excellence","year":"2004"},{"key":"10.1016\/j.ejim.2016.10.007_bb0335","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1046\/j.1365-2036.1998.00410.x","article-title":"Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies)","volume":"12","author":"Talley","year":"1998","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejim.2016.10.007_bb0340","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000103879","article-title":"Functional heartburn and non-erosive reflux disease","volume":"25","author":"Savarino","year":"2007","journal-title":"Dig Dis"},{"key":"10.1016\/j.ejim.2016.10.007_bb0345","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1136\/gut.2008.175810","article-title":"Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease","volume":"58","author":"Savarino","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.ejim.2016.10.007_bb0350","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.3748\/wjg.v19.i35.5787","article-title":"Overlap of functional heartburn and gastroesophageal reflux disease with irritable bowel syndrome","volume":"19","author":"de Bortoli","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejim.2016.10.007_bb0355","doi-asserted-by":"crossref","DOI":"10.1038\/ajg.2016.432","article-title":"Functional heartburn overlaps with irritable bowel syndrome more often than GERD","author":"de Bortoli","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ejim.2016.10.007_bb0360","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1136\/gutjnl-2011-300798","article-title":"Clinical, but not oesophageal pH\u2013impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease","volume":"61","author":"Zerbib","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.ejim.2016.10.007_bb0365","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/MEG.0b013e3282f52f95","article-title":"Inappropriate prescription of proton pump inhibitors on two pulmonary medicine wards","volume":"20","author":"Van Vliet","year":"2008","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejim.2016.10.007_bb0370","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1111\/j.1572-0241.2000.02680.x","article-title":"Overuse of acid-suppressive therapy in hospitalized patients","volume":"95","author":"Nardino","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejim.2016.10.007_bb0375","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1046\/j.1365-2036.2003.01600.x","article-title":"Hospital use of acid-suppressivemedications and its fall-out on prescribing in general practice: a 1-month survey","volume":"17","author":"Parente","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejim.2016.10.007_bb0380","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S0954-6111(03)00187-2","article-title":"Overuse of acid suppressive therapy in hospitalized patients with pulmonary diseases","volume":"97","author":"Niklasson","year":"2003","journal-title":"Respir. Med."},{"key":"10.1016\/j.ejim.2016.10.007_bb0385","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1742-1241.2004.00298.x","article-title":"Proton pump inhibitors: a survey of prescribing inan Irish general hospital","volume":"59","author":"Mat Saad","year":"2005","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.ejim.2016.10.007_bb0390","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/j.1365-2036.2005.02454.x","article-title":"Long-term use of acid suppression started inappropriately during hospitalization","volume":"21","author":"Zink","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejim.2016.10.007_bb0395","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1007\/s10620-005-3052-4","article-title":"Inadequate use of acid-suppressive therapy in hospitalized patients and its implications for general practice","volume":"50","author":"Scagliarini","year":"2005","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejim.2016.10.007_bb0400","doi-asserted-by":"crossref","first-page":"124","DOI":"10.4103\/1319-3767.33463","article-title":"Improper use of antisecretory drugs in a tertiary care teaching hospital: an observational study","volume":"13","author":"Mayet","year":"2007","journal-title":"Saudi J Gastroenterol"},{"key":"10.1016\/j.ejim.2016.10.007_bb0405","doi-asserted-by":"crossref","first-page":"122","DOI":"10.18553\/jmcp.2010.16.2.122","article-title":"Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress aulcer prophylaxis in a large managed care organization","volume":"16","author":"Thomas","year":"2010","journal-title":"J. Manag. Care Pharm."},{"key":"10.1016\/j.ejim.2016.10.007_bb0410","doi-asserted-by":"crossref","first-page":"288","DOI":"10.2174\/157488410793352067","article-title":"Overuse of PPIs in patients at admission, during treatment and at discharge in a tertiary Spanish hospital","volume":"5","author":"Ramirez","year":"2010","journal-title":"Curr. Clin. Pharmacol."},{"key":"10.1016\/j.ejim.2016.10.007_bb0415","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/SMJ.0b013e3181ce0e7a","article-title":"Overuse of acid suppression therapy in hospitalized patients","volume":"103","author":"Gupta","year":"2010","journal-title":"South. Med. J."},{"key":"10.1016\/j.ejim.2016.10.007_bb0420","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ejim.2010.11.009","article-title":"Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elederly","volume":"22","author":"Pasina","year":"2011","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.ejim.2016.10.007_bb0425","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/jhm.1901","article-title":"Inappropriate prescribing of proton pump inhibitors in hospitalized patients","volume":"7","author":"Reid","year":"2012","journal-title":"J. Hosp. Med."},{"key":"10.1016\/j.ejim.2016.10.007_bb0430","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1007\/s10620-015-3642-8","article-title":"The inappropriate prescription of oral proton pump inhibitors in the hospital setting: a prospective cross-sectional study","volume":"60","author":"Kelly","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejim.2016.10.007_bb0435","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.1365-2710.2000.00312.x","article-title":"Overuse of proton pump inhibitors","volume":"25","author":"Naunton","year":"2000","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.ejim.2016.10.007_bb0440","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1023\/A:1011278030001","article-title":"An evaluation of the use of proton pump inhibitors","volume":"23","author":"Walker","year":"2001","journal-title":"Pharm World Sci"},{"key":"10.1016\/j.ejim.2016.10.007_bb0445","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1572-0241.2003.07186.x","article-title":"Who is using chronic acid suppression therapy and why?","volume":"98","author":"Jacobson","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ejim.2016.10.007_bb0450","first-page":"e228","article-title":"Magnitude and economic impact of overutilization of antisecretory therapy in the ambulatory care setting","volume":"16","author":"Heidelbaugh","year":"2010","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.ejim.2016.10.007_bb0455","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1742-1241.2012.02973.x","article-title":"Appropriateness of proton pump inhibitor recommendations at hospital discharge and continuation in primary care","volume":"66","author":"Ahrens","year":"2012","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.ejim.2016.10.007_bb0460","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/apt.13649","article-title":"Medical and non-medical predictors of initiating long-term use of proton pump inhibitors: a nationwide cohort study of first-time users during a 10year follow up","volume":"44","author":"Haastrup","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejim.2016.10.007_bb0465","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/j.1572-0241.2007.01106.x","article-title":"The prevalence of and the clinical and demo-graphic characteristics associated with high-intensity proton pump inhibitor use","volume":"102","author":"Targownik","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ejim.2016.10.007_bb0470","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1365-2036.2008.03900.x","article-title":"Socio-demographic factors influence chronic proton pump inhibitor use by a large population in the Netherlands","volume":"29","author":"Van Boxel","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejim.2016.10.007_bb0475","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/j.1742-1241.2012.02921.x","article-title":"Proton pump inhibitors: are they overutilized in clinical practice and do they pose significant risk?","volume":"66","author":"Heidelbaugh","year":"2012","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ejim.2016.10.007_bb0480","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.dld.2016.05.018","article-title":"Are proton pump inhibitors really so dangerous?","volume":"48","author":"Savarino","year":"2016","journal-title":"Dig Liver Dis"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620516303624?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620516303624?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:04:26Z","timestamp":1718841866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620516303624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":96,"alternative-id":["S0953620516303624"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2016.10.007","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2016.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}